Item 5.03. Amendment to Articles of Incorporation or Bylaws; Change in Fiscal


           Year.

On April 24, 2023, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards and a periodic review of the amended and restated bylaws of PMV Pharmaceuticals, Inc. (the "Company") as currently in effect, the Company's board of directors (the "Board"), acting upon the recommendation of the Board's Nominating and Corporate Governance Committee, approved and adopted amended and restated bylaws (the "Amended and Restated Bylaws"), to be effective on June 8, 2023, the date of the Company's 2023 annual meeting of stockholders.

The Amended and Restated Bylaws, among other things:



    •     update and revise the advance notice procedures for the nomination of
          directors or the proposal of other business at stockholder meetings,
          including by adding a requirement that a stockholder seeking to nominate
          director(s) at a meeting of stockholders provide to the Company
          reasonable evidence that it has complied with the requirements of Rule
          14a-19 of the Securities Exchange Act of 1934, as amended, no later than
          five business days before the meeting;



    •     revise certain additional procedures related to stockholder meetings to
          conform to the provisions of the Delaware General Corporation Law, as
          recently amended (the "DGCL");



    •     revise the provision regarding board action by unanimous written consent
          in lieu of a meeting to conform to the provisions of the DGCL;



    •     update various provisions regarding directors, Board committees and
          officers; and



    •     make various updates throughout to conform to current Delaware law
          (including the recent amendments to the DGCL) and to make ministerial
          changes, clarifications, and other conforming revisions.

The foregoing description of the Amended and Restated Bylaws is not complete and is qualified in its entirety by reference to the full text thereof, a copy of which is attached hereto as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.




(d)  Exhibits.

Exhibit No.       Description

3.1                 Amended and Restated Bylaws of PMV Pharmaceuticals, Inc.,
                  effective June 8, 2023.

104               Cover Page Interactive Data File (embedded within the Inline XBRL
                  document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses